Introduction {#S1}
============

*LMNA* Gene and Its Products {#S1.SS1}
----------------------------

*LMNA* gene maps to chromosome 1q21.1-21.2 and is composed of 12 exons spanning around 25 kb. It encodes A-type nuclear lamins via alternative splicing ([@B49]; [@B90]): Lamin A and C (Lamin A/C) represents the two main isoforms, while Lamin C2 and AD10 are described in germ cells and cancer cells, respectively ([@B51]; [@B2]). A-type lamin proteins have a tripartite domain organization with a central rod domain, a short N-terminal head domain and a tail C-terminal domain. Unlike Lamin C, Lamin A is translated as Prelamin A, containing a carboxyl-terminal CaaX motif, which is then modified by carboxymethylation and farnesylation and undergoes sequential post-translational modifications to form mature Lamin A ([@B36]; [@B93]). Nuclear lamins are classified as type V intermediate filament (IF) proteins and represent the major elements that constitute the nuclear lamina (NL). In addition to their well-known structural role in the nucleus, Lamin A/C are increasingly considered as key players in regulating gene transcription through both direct and indirect modulation of chromatin organization, DNA replication and signal transduction pathways ([@B33]; [@B23]; [@B25]).

Unlike B-type lamins, the expression of A-type lamins is developmentally regulated and mostly occurs in differentiated cells ([@B89]). During mouse embryogenesis, Lamin A/C start to be expressed around day 8--9 in extra-embryonic tissues and few days later (day 10--12) in the embryo ([@B25]). The cell-specific and temporally regulated expression of these proteins supports a fundamental role of Lamin A/C in cell differentiation, lineage specification and tissue development ([@B89]; [@B13]).

Laminopathies {#S1.SS2}
-------------

Mutations in the *LMNA* gene cause laminopathies, a group of disorders characterized by phenotypically heterogeneous manifestations. Up to now a total of 498 *LMNA* mutations have been described^[1](#footnote1){ref-type="fn"}^ associated to more than 15 different phenotypes. Indeed, laminopathies can either specifically affect distinct tissues, including striated muscles, the peripheral nerves, or the adipose tissue, or present as a systemic disease affecting concomitantly several organs similar to premature aging syndromes. However, there is growing evidence of overlapping phenotypes, suggesting the presence of a real continuum within the disease.

Among the different phenotypes, cardiac involvement is one of the most prevalent and severe manifestations, being a hallmark of several laminopathies, such as Emery-Dreifuss muscular dystrophy, Limb-girdle muscular dystrophy 1B and Hutchinson-Gilford Progeria Syndrome (HGPS) ([@B27]; [@B4]; [@B83]). Despite the recent developments in the field, the understanding of the pathogenetic role of Lamin A/C in cardiac disease is still incomplete.

In this review we aim to provide an update on the state-of-the-art investigations in this area of research, drawing a definite line from the molecular mechanisms toward the clinical manifestations. Although investigators are still working on defining genotype/phenotype correlations, our goal is to highlight common molecular features that could link different *LMNA* variants to a similar clinical presentation.

From *Lmna* Variants to Cardiac Phenotypes {#S2}
==========================================

*LMNA* Variants {#S2.SS1}
---------------

The first reports that associate *LMNA* mutations to cardiac diseases date back to 1999 ([@B10]; [@B27]): these reports represented a revolution in the field, identifying for the first time *LMNA* mutations as responsible for dilated cardiomyopathy (DCM) associated with conduction system disease. [@B40] described several novel *LMNA* mutations, one missense (p.E203K, nucleotide c.G607A) in 14 individuals and one nonsense (p.R225X, nucleotide c.C673T) in 10 subjects: these patients were diagnosed with DCM and variable conduction system disease, and were free from any skeletal muscle phenotype. Few years later, other mutations in *LMNA* gene were described ([@B83],[@B84]; [@B72]): one nonsense mutation (815_818delinsCCAGAC) and some missense variants (p.N195K; p.Y259H; p.R166P). Overtime, *LMNA* gene emerged as the second most commonly mutated gene associated to familial cardiomyopathy (CMP), accounting for ∼6--8% of the cases ([@B37]) of idiopathic DCM, with this number raising up to 33% for cases presenting with both DCM and conduction defects ([@B53]).

Cardiolaminopathy {#S2.SS2}
-----------------

Cardiomyopathy caused by mutations in *LMNA* gene is referred to as cardiolaminopathy (LMNA-CMP). The disease is generally characterized by variable extent of ventricular dilation ([@B10]; [@B27]) or, less frequently, by left ventricular (LV) non-compaction ([@B74]).

LMNA-CMP has been linked to 165 unique mutations, distributed along the entire gene ([@B80]). However, the majority of the mutations occur in the head and in the rod domains and rarely in the tail domain ([@B27]; [@B40]). Pathogenic variants are mainly missense and nonsense mutations, while fewer small deletions/insertions have been identified ([@B26]; [@B94]). Haploinsufficiency has been suggested as mechanism of disease in patients carrying truncating variants, while missense mutations have been proposed to act mainly through a dominant negative pathway. Subjects with truncating mutations have been associated to an earlier onset of cardiac conduction defects and atrial arrhythmias and a lower LV ejection fraction (EF), than those with missense mutations ([@B62]). However, so far there is still lack of knowledge explaining the link between specific *LMNA* mutations and a defined phenotype, and the severity and the progression of the disease have marked interindividual variability, not only among unrelated probands, but also within members of the same family. This supports the concept that the final phenotype results not only from the single *LMNA* mutation, but is also influenced by modifying genes or environmental cues, similarly to what has been reported in some families with titin and desmin mutations ([@B60]; [@B32]; [@B71]). Whole-exome and whole-genome sequencing studies will unequivocally facilitate the investigation of the genetics behind the disease and allow a comprehensive understanding of the mechanisms underlying the final clinical presentation.

Cardiac Conduction System Disease and Arrhythmias {#S2.SS3}
-------------------------------------------------

The clinical course of LMNA-CMP is characterized by a high rate of major cardiac events such as sudden cardiac death (SCD), malignant ventricular tachycardia (VT), extreme bradycardia due to a high degree of atrioventricular block (AVB) and end-stage heart failure. What is intriguing is the common finding that laminopathies often manifest as primary arrhythmia. Bradyarrhythmias and supraventricular tachyarrhythmias as atrial fibrillation and flutter often anticipate by decades the development of DCM. For this reason, genetic screening should be considered in young patients presenting with new AVB or atypical atrial arrhythmias, even in the absence of LV dysfunction. In the study by [@B45], only one-half of patients have an LVEF \< 50% at the initial medical consultation.

The pathophysiological mechanisms underlying the arrhythmic phenotype are still not well elucidated. Systolic dysfunction, male sex, non-missense mutations and non-sustained VT are considered predictors of malignant ventricular arrhythmias in LMNA-CMP ([@B82]; [@B34]; [@B45]; [@B62]). However, such risk factors are debated in some studies ([@B62]; [@B66]) and it was recently shown in a large cohort of DCM patients, that carriers of *LMNA* variants experience the highest rates of SCD/VT/ventricular fibrillation (VF), which was independent of the LV EF ([@B29]). Further studies need to be conducted in order to clarify to which extent phenotypic differences among the different cohorts of patients are dependent on genetic background rather than on specific *LMNA* variants.

Clinical Presentation {#S2.SS4}
---------------------

The presentation of DCM does not show specific characteristics and the expression of the DCM pattern was found to be age-dependent, with development of the phenotype between 20 and 39 years of age in two thirds of the cases and complete penetrance by 60 years ([@B4]). The "red flags" predicting higher chance of *LMNA* mutations are the concomitant presence of conduction defects and skeletal muscle involvement, even if creatine phosphokinase (CPK -- serum marker of muscular damage) is elevated only in one third of the cases ([@B27]; [@B70]). [@B4] showed that approximately 33% of patients with AVB and cardiomyopathy carries a *LMNA* mutation. For this reason, screening for *LMNA* mutations in young patients with idiopathic DCM, especially when it is associated with atrial arrhythmias and/or AVB, is important for prognosis and genetic counseling.

Patients who have both cardiac and neuromuscular manifestations more commonly experience bradyarrhythmias and atrial fibrillation compared to patients with solely cardiac phenotypes, despite having no differences in structural heart disease. In this group of patients cardiac abnormalities do not strictly correlate with the severity of the neuromuscular involvement, which may suggest distinct pathogenetic mechanisms ([@B7]; [@B35]; [@B66]). However, a recent study on a small cohort of patients showed that the neuromuscular presentation was associated with earlier cardiac involvement, characterized by a linear and progressive evolution from rhythm disorders to cardiomyopathy ([@B24]).

Prognosis and Risk Stratification {#S2.SS5}
---------------------------------

Cardiolaminopathy often presents an aggressive and rapid evolution, with a worse natural history compared to other forms of non-ischemic dilated cardiomyopathies and have higher prevalence of malignant arrhythmias and cardiac transplantation ([@B64]; [@B42]).

Positive genetic testing for *LMNA* mutations has crucial clinical and prognostic implications. Mortality in patients with LMNA-CMP is estimated to be 40% at 5 years ([@B64]), whereas 45% suffered SCD or aborted SCD. Currently, *LMNA* mutations represent the only genetic background in DCM that influences international guidelines-based timing of ICD therapy in primary prevention, regardless of LV EF values ([@B69]; [@B68]).

Recently, a new 5-year prediction model for life threatening ventricular tachyarrhythmia (LTVTA) has been proposed ([@B85]) to assist us in deciding whether or not a candidate is eligible for the placement of an ICD implantation (online calculator available at <http://lmna-risk-vta.fr/>). Predictors of LTVTA in the analyzed sample were male sex, non-missense *LMNA* mutation, 1st degree and higher AV block, non-sustained VT and LV EF. The risk threshold used enabled reclassification of 28.8% of patients compared with the guidelines-based approach.

New Molecular Targets Under Clinical Investigation {#S2.SS6}
--------------------------------------------------

Currently, three new molecular targets, emerged from biochemical studies, are under investigation as possible pharmacological strategies to treat LMNA-CMP. The first approach involves a selective oral inhibitor of the p38 MAPK pathway is currently under a phase III clinical trial^[2](#footnote2){ref-type="fn"}^. The second approach regards the application of mTOR pathway inhibitors that have shown promising improvements in terms of LV size and function in animal models ([@B18]), and the third approach focuses on PDGFR blockers and their ability to ameliorate the arrhythmic phenotype in *in vitro* models ([@B46]).

Molecular Hypotheses Behind the "Clinical Scenario" {#S3}
===================================================

As mentioned above, 498 different mutations in *LMNA* gene have been reported, of which 165 associated with LMNA-CMP. Since the discovery of the *LMNA* gene as causative of laminopathies, more than 1000 research and clinical studies have been published, aiming to establish a causal correlation between morphological and functional defects of laminopathic cells and the heterogeneous clinical phenotypes of this group of disorders. Although several hypotheses on the potential mechanisms have emerged from these studies, a unique view on the role of Lamin A/C defects in laminopathies is still missing. The same scenario also applies to CMPs due to *LMNA* mutations and the functional role of A-type lamins in the mammalian heart. Studies on animal models either lacking *Lmna* gene or transgenic for specific human *LMNA* variants, together with evidence from human cardiac models generated through iPSC (induced Pluripotent Stem Cell) technology have significantly contributed to increase our knowledge in the field of cardiolaminopathy. Independent investigations have proposed several hypotheses to explain molecular mechanisms underlying Lamin A/C action in the heart and their link to disease traits.

[@B61] proposed that the softer nuclei's structure associated to *LMNA* mutations and the resulting morphological abnormalities may be the molecular events at the basis of the Lamin-related cardiac phenotypes. This has been specifically referred to as the "structural hypothesis," attributing the lamin-associated phenotypes to structural defects. Furthermore, being an integral part of the LINC complex (Linker of Nucleoskeleton and Cytoskeleton), A-type lamins may also contribute in regulating the structural architecture of the contractile tissue, conferring resistance and protection against any mechanical stress ([@B79]); this view was later referred to as the "mechano-transduction hypothesis."

Alongside these "structural hypotheses," a "gene transcription hypothesis" also emerged, starting from previous evidence suggesting a role of the inner nuclear membrane in regulating chromatin organization (and gene expression). A study from [@B92] provided the first piece of evidence of a link between NL and chromatin regulation: the authors finely demonstrated a specific binding between the human chromodomain proteins HP1 and the integral protein of the inner nuclear membrane LBR (Lamin B Receptor) in *Drosophila*, portraying for the first time, the association between heterochromatin and the inner nuclear membrane in eukaryotic cells. These findings added a new function to Lamin A/C proteins, demonstrating that their biological role is not just restricted to the control of nuclear shape and mechano-transduction, but extends to the active regulation of gene transcription. Following this trail, many other studies subsequently showed that several binding factors are able to simultaneously interact with the chromatin and the NL ([@B19]; [@B87]; [@B86]; [@B14]). This gene transcription hypothesis relies on a two-step model, in which the NL regulates transcription factors, either by sequestering them to the nuclear periphery -- usually transcriptionally inactive -- or by a mechanism that involves activation of specific signaling pathways, such as ERK1/2 ([@B5]; [@B57]; [@B17]). In addition to this, Lamin A/C is also able to directly bind chromatin, modulating its spatial organization. The interaction between chromatin and A-type lamins occurs at definite genomic regions, defined as lamin-associated domains (LADs) ([@B67]). Interestingly, there is evidence showing a remodeling of LADs, in particular those tissue-specific (facultative LADs), in presence of Lamin A/C mutations. These rearrangements do not exclusively occur at the nuclear periphery, but also affect expression of genes located at the nuclear interior ([@B11]). For example, repositioning of *T/BRACHYURY* gene from the nuclear periphery toward the nuclear interior has been reported in fibroblasts of patients affected by familial partial lipodystrophy of Dunnigan type 2 (FPLD2) ([@B12]). [@B59] also showed that knockdown of Lamin A/C in human HeLa cells, cause relocation of *CFTR* gene in the nuclear interior, without affecting the position of the neighboring *GASZ* and *CORTBP2* genes. On the contrary, we recently demonstrated a preferential localization of *SCN5A* gene by the nuclear periphery in human iPSC-CMs carrying the p.K219T *LMNA* mutation, resulting in the inhibition of the expression of the gene and thus leading to reduction of sodium currents and impaired cell excitability ([@B73]).

In addition to this, lamin-chromatin interactions may also occur through several binding factors, identified as interacting-mediators between Lamin A/C and chromatin compartments ([@B44]); interestingly some of these have been described as essential elements to regulate transcription of key tissue-specific genes, also in the heart ([@B12]; [@B73]). From this perspective, this mechanistic model of Lamin A/C action can be more accurately defined as "chromatin hypothesis"; importantly, Lamin A/C-driven chromatin regulation has been recently started to be addressed also in the field of cardiolaminopathy by studies from different research groups including ours ([@B8]; [@B56]; [@B73]). The general view emerging from chromosome conformation capture studies (HiC), a method to study three-dimensional architecture of genomes enabling to distinguish between transcriptionally active (A) and inactive (B) compartments, is that Lamin A/C haploinsufficiency is associated to an increase of intra-chromosomal interactions (meaning interactions between two active compartments -- A-A), without interfering with inter-chromosome interactions (with different transcriptional status -- A-B) or inducing massive changes in gene transcription ([@B8]). According to that, four dimensional genome conformation (referred as spatial assemblies of heterochromatic topological associated domains -- TADs, or "TAD cliques") showed silencing of developmental genes in human adipose-derived stromal cells (ASCs), without reporting any A to B switch ([@B65]). On the other hand, the study from [@B46] associated Lamin A/C haploinsufficiency, caused by a different frameshift *LMNA* mutation, with relevant LAD alterations, that are responsible for substantial changes in gene expression profile leading to altered activation of PDGF pathway. Although the "chromatin hypothesis" has been associated so far to few specific variants, it is likely that similar regulatory mechanisms are driven also by other Lamin A/C mutations, reinforcing the link between changes in transcriptional regulation and chromatin organization occurring in Lamin A/C mutant cells and the respective clinical phenotype.

Consistently, chromatin remodeling and the associated transcriptional changes of disease-relevant genes, is also the prevalent model proposed for the HGPS, the most severe *LMNA*-dependent disease ([@B30]; [@B31]; [@B1]). Interestingly, a very recent study by [@B39] further contributed to the field describing a new regulatory mechanism by Lamin A/C. Specifically, the authors describe a new regulatory function of the nucleoplasmic Ser22-phosphorylated (pS22) Lamin A/C, that they found specifically bound to a subset of active enhancers, and show the acquisition of new pS22-Lamin A/C binding site in HGPS cells, leading to upregulation of clinically relevant genes and potentially underlying the mechanism behind the disease phenotype.

Overall, data obtained so far from different studies in the field support a model by which all the proposed hypotheses can be causally connected, rather than mutually exclusive. As suggested by [@B63] in their Perspective, it is likely that a robust link between the structural abnormalities of laminopathic nuclei ([@B61]; [@B28]) and either chromatin modifications or reorganization exists, thus contributing to a multifaceted mechanistic model underlying the pathogenesis of the disease.

Mouse Models {#S4}
============

In the past two decades, several mouse models have been generated, either reproducing patients' mutations (*LMNA* transgenic mice) or studying the consequences of *Lmna* deficiency (*Lmna* knockout mice). *Lmna^--/--^* mouse developed muscular dystrophy, DCM, neuropathy and displayed retarded growth rate, reduced stores of white fat and cardiac arrhythmia ([@B78]). These mice generally die by 8 weeks of age.

The heterozygous (*Lmna*^±^), with 50% of Lamin A/C expression, manifest conduction system diseases, ventricular dilatation later in adult life and generally die by 8 months of age ([@B15]). At the molecular level, both the *Lmna* null and the *Lmna* haploinsufficiency mice showed altered desmin pathway and defective force transmission, leaning toward the mechano-transduction hypothesis. Furthermore, those models also showed an increase of pro-adipogenic factors (PPAPγ and CEBP/α), whereas Wnt-10/β-catenin levels were decreased ([@B81]). Another two *Lmna* knock-out models, *Lmna^*GT*--/--^* and *Lmna^*delK*32/delK32^*, have also contributed significantly to establish the role of Lamin A/C in postnatal maturation, showing developmental impairment and growth retardation, that mostly affect the adipose tissue, the skeletal muscle and the heart ([@B43]; [@B9]).

Recently, the generation of *Lmna*^H222P^ and *Lmna*^N195K^ transgenic mice ([@B5]; [@B55]) successfully recapitulated a faithful model of skeletal muscle and DCM, with no phenotype at neonatal stage and displaying disease traits similar to patients. The pathogenesis of *Lmna*^H222P^ mice was linked to elevated MAP kinase 1/2 (ERK1/2) and AKT/mTor signaling pathways ([@B57]; [@B16]). [@B3] recently further characterized this model, describing a novel relationship between the elevated levels of ERK1/2 and nuclear positioning in cardiomyocytes (CMs) isolated from *Lmna*^H222P/H222P^. The authors showed that a single phosphorylation site in the formin homology domain-containing proteins (FHOD) can be targeted by ERK1/2, changing cell polarity and negatively regulating cell migration. Nuclear positioning is strictly linked to the formation of the sarcomeres during skeletal muscle maturation ([@B75]). Consistently, the authors showed that H222P mutation in the *LMNA* gene is associated to altered nuclear positioning and formation and function of sarcomeres, contributing to the pathogenesis of cardiomyopathy. On the other hand, *Lmna*^N195K^ mice displayed an abnormal expression and/or localization of connexin 40 and connexin 43 and sarcomeres disorganization associated to the main DCM phenotype and conduction system defects ([@B55]). A complete list of the described mouse models and their relevant cardiac phenotypes and molecular characteristics are provided in the [Table 1](#T1){ref-type="table"}.

###### 

Mouse models of cardiolaminopathy.

  **Mouse model**                                                                  **Phenotype**                                                                                                                                  **Molecular mechanism**                                                                                                                                        **References**
  -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------
  ***Lmna***^--/--^                                                                Muscular dystrophy; DCM; signs of axonal neuropathy; reduction of adipose tissue; death by 8 weeks of age                                      Structural and Mechano-transduction hypotheses based on abnormal desmin network and defective force transmission                                               [@B78]; [@B22]; [@B61]
  ***Lmna***^+/--^ (Haploinsufficiency)                                            Phenotypes are less severe than in *Lmna^--/--^*Conduction system defects; DCM; apoptosis of the conduction tissue; death by 8 months of age   Structural and Mechano-transduction hypotheses:--Abnormal desmin network and defective force transmission;--Mechanical-stress induced apoptosis                [@B88]; [@B15]; [@B20]
                                                                                                                                                                                                                                  Gene transcription hypothesis: --Reduced expression of *Egr-1* gene due to a direct interaction between Lamin A/C and c-Fos in response to pressure overload   [@B20]
  ***Lmna***^N195K^ knock-in                                                       DCM-CD                                                                                                                                         Structural and Signaling hypotheses: --Misexpression/mislocalization of Cx40 and Cx43--Abnormal desmin organization                                            [@B55]
  ***Lmna***^H222P^                                                                Muscular dystrophy and DCM-CD                                                                                                                  Structural and signaling hypotheses: --Alteration of ERK/MAPK pathway                                                                                          [@B5]; [@B57]; [@B18]; [@B58]; [@B16]; [@B17]; [@B3]
                                                                                                                                                                                                                                  --Link between ERK1/2 and repositioning of cell nuclei                                                                                                         [@B3]
  ***Lmna***^GT^*^--^*^/^*^--^* (*Lmna* null mouse to study cardiac development)   Growth retardation; defects in heart development; decreased amount of subcutaneous fat; death by 2--3 weeks of age                             Alteration in gene transcription profile: delayed muscle and cardiac differentiation/maturation.                                                               [@B43]
  ***Lmna***^delK32/delK32^ (*Lmna* null mouse to study cardiac development)       Growth retardation; defects in heart development; decreased amount of subcutaneous fat; death by 2--3 weeks of age                             Gene transcription profile defects: deregulation of genes involved in cell metabolism and adipogenesis.                                                        [@B9]

DCM, dilated cardiomyopathy; DCM-CD, dilated cardiomyopathy-conduction defect; Cx40, Connexin 40; Cx43, Connexin 43.

To conclude, despite likely species-specific limitations, studies conducted so far using mouse models have been fundamental to identify signaling pathways relevant to development of new therapeutics, such as the previously mentioned p38 inhibitor ARRY-371797 -- already in Phase III clinical trial (NCT02057341) -- and the N-acetyltransferare 10 (NAT10) inhibitor, Remodelin ([@B6]). However, although these are important achievements, there is still an important lack of knowledge on the pathogenetic mechanisms underlying this complex disease and therefore further research in the field is mandatory to comprehensively tackle its molecular basis and develop more specific and effective therapies ([@B77]; [@B95]).

Cardiomyocytes From iPscs: a Powerful Platform to Model Human Cardiolaminopathy {#S5}
===============================================================================

The development of iPSC technology has been a groundbreaking revolution in all areas of research, allowing us to generate *in vitro* any cell type of interest, including human CMs, in which pathogenic mechanisms of diseases may be fully investigated ([@B91]; [@B54]; [@B50]; [@B47]). Research in the cardiolaminopathy field has also benefit of this technology, since use of iPSC-based models allowed us to overcome the major limitations linked to investigation on animal models and non-cardiac primary cells. Indeed, recreating human phenotypes in mice may not be feasible, due to species-specific differences between mice and humans, especially in relation to the cardiovascular system (i.e., electrophysiological properties of cardiac cells) ([@B21]). On the other hand, obtaining cells from the human heart may be difficult, due to the limited access the organ and the poor survival of the heart cells grown *ex vivo*. For these reasons studies on cardiolaminopathies so far have been mainly conducted on other somatic cell types, such as fibroblasts, skeletal muscle cells and adipocytes, which are easy to access and to maintain *in vitro* ([@B38]).

Thus far seven independent studies have investigated human LMNA-CMP using iPSCs either derived from patients carrying different *LMNA* mutations or generated through genome editing ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). The first set of studies -- those published from 2011 to late 2018 -- were mainly descriptive, reporting morphological and functional characteristics of cardio-laminopathic cells: these studies thus confirmed the abnormal morphology of cell nuclei and investigated the susceptibility to electrical and mechanical stresses and the alteration of excitation-contraction coupling in contractile cardiac cells ([@B38]; [@B76]; [@B48]). The reported phenotypes were generally ascribed to a structural and/or mechano-transduction hypotheses, in which a generated physical force is responsible for the sarcomeres' disorganization and contribute to alter the NL structure. In a few studies, defects due to *LMNA* mutations were associated to alteration of ERK1/2 signaling pathway, that itself influences the correct assembly of the sarcomeres ([@B76]; [@B17]).

More recently, similarly to what reported in other cellular models of laminopathy, the pathogenesis of the LMNA-CMP has been linked to the "gene expression/chromatin organization hypothesis," showing a causal association between *LMNA* mutations, transcription and specific cell phenotypes ([@B8]; [@B46]; [@B73]). More specifically, these studies utilized models of cardiolaminopathy carrying different mutations (i.e., K219T, R225X, and R190W) and found an altered expression of genes of key pathways for CMs functionality. Whether these effects on gene expression are preferentially mediated by remodeling of LADs or the results of a rearrangement at a different level of chromatin organization/regulation (i.e., TADs; change of affinity of mutant Lamin A/C for chromatin binding proteins) still need to be clearly determined.

What is important to highlight, from the functional point of view, is that the robust association between the disease phenotypes and *LMNA* defects was supported by the experiments conducted in isogenic iPSC paired lines, in which the *LMNA* mutations were corrected or inserted through CRISPR/Cas9-based ([@B8]; [@B73]) or TALEN ([@B46]) technologies. Also, these studies provided the identification of new potential therapeutic targets (*SCN5A* gene and PDGF pathway) to treat cardiolaminopathy.

These are important achievements in the field but, with the constant amelioration of the protocols for CM differentiation, we expect to improve even further and to gain more insights into the pathogenetic mechanisms of the disease. Indeed, data available so far come from studies on human CMs obtained from iPSCs mostly through 2D-based differentiation protocols, known to generate CMs with an immature fetal-like phenotype, meaning that they lack some of the structural (i.e., T-tubules, sarcomeric alignment), functional (i.e., calcium handling and contractile properties differences) and metabolic (i.e., glycolysis vs. fatty acid oxidation) properties typical of an adult CM. These properties are highly desirable for drug screening and for modeling specific, adult-onset traits of disease ([@B41]; [@B52]). Given the developmentally regulated expression of Lamin A/C and the complexity of disease phenotype, cell immaturity is likely to impact also on LMNA-CMP modeling, and some important traits of the disease may have been missed so far. The iPSC field is now moving toward the application of 3D-based differentiation protocols, shown to improve maturation of the differentiated CMs, enhancing the potential of iPSC-based cardiac platforms for both disease modeling and drug screening purposes, and from which the cardiolaminopathy field will also benefit in the near future.

Conclusion {#S6}
==========

Consensus has yet to be reached on the pathogenetic mechanism of cardiolaminopathy and researchers in the field are still trying to finely dissect the molecular role of A-type lamins in the heart and to establish clear genotype/phenotype correlations. Indeed, cardiolaminopathy is a quite complex diseases, with patients exhibiting extremely variable phenotypes, as regards of either specific clinical manifestations or the severity and progression of the disease.

Decades of studies in the field clearly sustain a view in which epigenetic regulations and environmental stimuli are likely to act alongside a single *LMNA* mutation in determining the final cardiolaminopathy phenotype. More recent studies have started to unravel those mechanisms showing (a) the involvement of other "actors" cooperating with a defective Lamin A/C ([@B73]) and (b) the dual impairment of mechano-signaling and gene expression in laminopathies ([@B63]), supporting a holistic model in which the different mechanistic hypotheses cooperate with different extents to the final clinical phenotypes observed in patients ([Figure 1](#F1){ref-type="fig"}).

![Overview on Lamin A/C proteins localization and on major mechanistic hypotheses underlying cardiac phenotypes. **(A)** Graphic representation of Lamin A/C proteins localization within the cell: Lamin A/C can be found both, at the periphery and in the nuclear interior. In the nucleus, Lamin A/C have a key structural function and are also involved in chromatin organization and regulation of genes transcription. This latter function can be mediated by both peripheral and nucleoplasmic Lamin A/C forms. Besides their role inside the nucleus, Lamin A/C also impact on cellular processes taking place at the outer part of the nuclear envelope: Lamin A/C indeed interact with the nucleo-cytoskeletal proteins, here indicated as LINC complex (i.e., SUN1, NESPRIN, intermediate filaments). The LINC proteins, in turn, interact with other cytoskeletal proteins (i.e., alpha-actinin), contributing to the maintenance of nuclear and cytoskeletal structure and effectors of specific signaling pathways. **(B)** The diagram shows the main mechanistic hypotheses underlying clinical manifestations of cardiolaminopathies. The arrows connecting the blue boxes indicate that these hypotheses are not mutually exclusive, but, instead, are potentially interconnected and all contribute to the final phenotype. **(C)** Clinical manifestations typically associated to LMNA-CMP.](fphys-11-00761-g001){#F1}

We strongly believe that future studies will further support this global model, unveiling novel disease-relevant pathways and specific targets to treat LMNA-CMP.
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